Esperion to Participate in a Key Life Sciences Event
ANN ARBOR, Mich. — Esperion (NASDAQ: ESPR) recently announced its upcoming participation in the Citizens Life Sciences Conference. This significant event is scheduled for May 8 and will commence at 12:30 p.m. ET. Enthusiasts and stakeholders can look forward to an engaging webcast highlighting the latest developments in the biopharmaceutical sector.
Webcast Access and Replay Information
The live webcast for the conference will be available through the investor and media section of Esperion's official website. Those unable to attend live will have the opportunity to access a replay, which will be available approximately two hours post-event and remain archived for around 90 days.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is dedicated to addressing critical gaps in cardiovascular care through pioneering biopharmaceutical innovations. The company is particularly known for its development and commercialization of the first oral, once-daily, non-statin medications that have received FDA approval. This advancement is particularly significant for patients who are at risk for cardiovascular diseases and struggle with elevated low-density lipoprotein cholesterol (LDL-C).
Groundbreaking Clinical Trials
Esperion's medications are founded on the robust evidence gathered from the CLEAR Cardiovascular Outcomes Trial, which included nearly 14,000 patients. The data has been pivotal in validating the efficacy of these new therapeutic options. Moving forward, Esperion is committed to expanding its portfolio with next-generation therapies, including ATP citrate lyase inhibitors (ACLYi).
Innovations and Future Directions
The company’s focus on advancing ACLYi showcases its commitment to rational drug design, which aims to create potent and specific inhibitors utilizing allosteric mechanisms. This innovative approach could redefine treatment options for patients with coronary artery disease and further solidify Esperion’s position as a leading biopharmaceutical player.
Global Expansion and Partnerships
Esperion is evolving from a national player to a global presence through strategic commercial execution and international collaborations. This growth is vital for its mission to enhance patient care worldwide.
Engagement with the Investor Community
Esperion remains devoted to maintaining transparent communication with its investors and the public. For more detailed updates, stakeholders are encouraged to explore their official online presence and social media channels. Through these platforms, Esperion shares insights into its research, product offerings, and corporate progress.
Contact Information for Investor Relations
For inquiries, Esperion provides accessible contact details for both investors and media representatives. Investors can connect with Alina Venezia at (734) 887-3903 or via email at investorrelations@esperion.com. For media-related matters, Tiffany Aldrich can be reached at (616) 443-8438 or through corporateteam@esperion.com.
Frequently Asked Questions
What is the focus of Esperion's participation in the conference?
Esperion aims to showcase its innovative biopharmaceutical solutions for cardiovascular health during the conference.
How can I access the live webcast?
The live webcast will be available on Esperion's investor and media section of their official website on the day of the conference.
What are the key products developed by Esperion?
Esperion has developed the first FDA-approved oral, once-daily, non-statin medications to address elevated LDL-C levels in at-risk patients.
What is the CLEAR Cardiovascular Outcomes Trial?
This pivotal trial supported the efficacy of Esperion's medications and included nearly 14,000 patients, providing critical data for their products.
How can I reach out for investor inquiries?
Interested investors can contact Alina Venezia at (734) 887-3903 or via email at investorrelations@esperion.com.
